课题基金 / 基金详情

Nanoparticle imaging method for drug discovery and cancer therapy in humans

Nanoparticle imaging method for drug discovery and cancer therapy in humans
用于人类药物发现和癌症治疗的纳米颗粒成像方法
批准号:
EP/R04192X/1
负责人:
Richard Bayford
金额:
$31.53万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2018
资助国家:
英国
项目状态:
已结题
起止时间:
2018 至 --

项目摘要

项目成果

Richard Bayford的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
A novel nanoparticle imaging method for drug discovery and cancer therapy in humans will be created based on the combination of gold nanoparticles (AuNPs) as contrast agent, activated with radio-frequency (RF) and imaged with electrical impedance tomography (EIT). This would use the advantage that EIT is very sensitive to impedance change due to temperature changes from the RF activation of the AuNPs. It would have the potential to replace positron emission tomography (PET) imaging with the advantage of no ionising radiation, lower cost and the high temporal resolution of EIT. This would have a wider range of applications including tracking nanoparticles used to target cancer cells and drug discovery. Key to their use is the ability to target the desired cells for therapy; at present transmission electron microscopy (TEM) or photo-thermic microscopes can be used to image them on cell lines or in some case samples removed from the patient but not in vivo. Technology like PET uses ionising radiation and MRI does not use AuNPs, as they are paramagnetic and would require many images to track the particles, which would not be cost effective. The new imaging technology could also be combined with radiotherapy to confirm the location of the AuNPs. Researchers have investigated the concept of kilovoltage radiosurgery with AuNPs for AMD (Age-related Macular Degeneration). They concluded that a prescribed dose of x-ray radiation could be delivered using almost half of the radiation when compared to a treatment without AuNPs allowing reduction of the dose delivered to the neighbouring organs such as the retinal/optic nerve by 49%.Nanoparticles have been suggested for a range of clinical applications, including as contrast agents, for drug delivery and for treatment or therapy. Nanoparticles may be delivered to the patient by injection, by ingestion or by topical application to the skin, for example. Nanoparticles are constructed to perform a function in the body, for example to reach a particular target in the body such as an organ or a tumour. Once at the target, the nanoparticles may deliver a payload or play a role in some other function such as imaging or therapy. Thus, for example, if the nanoparticle is to target a tumour, cancer biomarkers may be attached to the scaffold core. Alternatively, antibodies to specific bacteria may be attached to the NPs in order to detect sepsis.The ability to track drug delivery by attaching a nanoparticle in the human body or using AuNPs to kill cancer cells would transform cancer treatment and other conditions, for example, if cancer metastasises then AuNPs could prove a method of destroying cancer cells. Many drugs, even those discovered using the most advanced molecular biology strategies, have unacceptable side effects due to the drug interacting with healthy tissues that are not the target of the drug. The goal of a targeted drug delivery system is to prolong, localize and target however roughly 99% of the drugs administered do not reach the target site. Side effects limit our ability to design optimal medications for many diseases such as cancer, neurodegenerative diseases, and infectious diseases. Also at present technologies to track drugs use mass spectroscopy and animal experiments requiring large scale computing to provide only one image of the accumulation of the drug. The novel approach proposed in this would revolutionise this and could provide hundreds of images a second if needed. This project has considerable potential to optimise targeting.
期刊论文(6)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1039/d1na00318f
发表时间: 2021-09-14
期刊: Nanoscale advances
影响因子: 4.7
作者: []
通讯作者:
On the optimal plasmonic resonances in gold nanospheres embedded in dispersive media
关于嵌入分散介质中的金纳米球的最佳等离子体共振
DOI: 10.23919/ursi-emts.2019.8931489
发表时间: 2019
期刊:
影响因子: --
作者: [Nordebo S]
通讯作者: Nordebo S
DOI: 10.1038/s41598-021-83869-8
发表时间: 2021-02-24
期刊: Scientific reports
影响因子: 4.6
作者: [de Gelidi S, Bardill A, Seifnaraghi N, Wu Y, Demosthenous A, Rahtu M, Kallio M, Bayford R]
通讯作者: Bayford R
Exploiting the Efficacy of Tyro3 and Folate Receptors to Enhance the Delivery of Gold Nanoparticles into Colorectal Cancer Cells In Vitro
利用 Tyro3 和叶酸受体的功效增强金纳米颗粒体外递送至结直肠癌细胞中
DOI: 10.21203/rs.3.rs-101290/v1
发表时间: 2020
期刊:
影响因子: --
作者: [Patel N]
通讯作者: Patel N
CoRLEIT, Covid Regional Lung EIT
  • 批准号:
    EP/V044036/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $68.43万
  • 财政年份:
    2020
  • 负责人:
    Richard Bayford
  • 依托单位:
PNEUMACRIT: Preterm Neonate / neonatal Embedded Universal Microelectronic wearable Acquisition For Cardio Respiratory Intensive Therapy
  • 批准号:
    EP/T001240/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $100.09万
  • 财政年份:
    2020
  • 负责人:
    Richard Bayford
  • 依托单位:
New imaging methods for the detection of cancer biomarkers
  • 批准号:
    EP/G061572/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $99.41万
  • 财政年份:
    2009
  • 负责人:
    Richard Bayford
  • 依托单位:
A NOVEL ANALOGUE BIO-IMPEDANCE SYSTEM-ON-A-CHIP FOR MONITORING OF NEONATE LUNG FUNCTION
  • 批准号:
    EP/E031633/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $22.44万
  • 财政年份:
    2007
  • 负责人:
    Richard Bayford
  • 依托单位:
国内基金
海外基金
PET/MR多模态分子影像在阿尔茨海默病炎症机制中的研究
  • 批准号:
    82372073
  • 项目类别:
    面上项目
  • 资助金额:
    48.00万元
  • 批准年份:
    2023
  • 负责人:
    张淼
  • 依托单位:
用于小尺寸管道高分辨成像荧光聚合物点的构建、成像机制及应用研究
  • 批准号:
    82372015
  • 项目类别:
    面上项目
  • 资助金额:
    48.00万元
  • 批准年份:
    2023
  • 负责人:
    熊丽琴
  • 依托单位:
基于影像代谢重塑可视化的延胡索酸水合酶缺陷型肾癌危险性分层模型的研究
  • 批准号:
    82371912
  • 项目类别:
    面上项目
  • 资助金额:
    48.00万元
  • 批准年份:
    2023
  • 负责人:
    吴广宇
  • 依托单位:
神经系统中大麻素CB1受体与周期性细胞骨架相互作用的机制和功能研究
  • 批准号:
    32100555
  • 项目类别:
    青年科学基金项目(C类)
  • 资助金额:
    30.0万元
  • 批准年份:
    2021
  • 负责人:
    李卉
  • 依托单位: